重组人血管内皮抑素/恩度

重组人血管内皮抑素/恩度的相关文献在2007年到2020年内共计86篇,主要集中在肿瘤学、临床医学、内科学 等领域,其中期刊论文86篇、专利文献217188篇;相关期刊39种,包括中国保健营养、现代生物医学进展、实用临床医药杂志等; 重组人血管内皮抑素/恩度的相关文献由329位作者贡献,包括秦叔逵、王琳、陈映霞等。

重组人血管内皮抑素/恩度—发文量

期刊论文>

论文:86 占比:0.04%

专利文献>

论文:217188 占比:99.96%

总计:217274篇

重组人血管内皮抑素/恩度—发文趋势图

重组人血管内皮抑素/恩度

-研究学者

  • 秦叔逵
  • 王琳
  • 陈映霞
  • 刘秀峰
  • 龚新雷
  • 华海清
  • 吴春娇
  • 姜子瑜
  • 姜苗
  • 杨宁蓉
  • 期刊论文
  • 专利文献

搜索

排序:

年份

作者

    • 潘欢; 陈唯唯; 滕弥明; 董洪敏; 王文玲; 王刚; 陈娟; 李小凯; 李国栋; 陈望花
    • 摘要: 目的:观察重组人血管内皮抑制素(恩度)窗口期联合化疗治疗晚期大肠癌的临床疗效.方法:选取2014年6月至2018年6月于贵州省肿瘤医院就诊的不可手术的晚期大肠癌患者120例,随机分为重组人血管内皮抑制素窗口期联合化疗组(试验组)及重组人血管内皮抑制素常规方案联合化疗组(对照组)各60例.试验组方案:重组人血管内皮抑制素15 mg/d,d1~d7,间歇7天重复,用药14天为1个周期,化疗于每周期使用重组人血管内皮抑制素第5天(窗口期)开始;对照组方案:重组人血管内皮抑制素15 mg/d,d1~d14,间歇7天重复,21天为1个周期,化疗于重组人血管内皮抑制素治疗第1天开始;两组均采用mFOLFOX6或FOLFIRI方案化疗.对比分析两组的临床疗效.结果:1)试验组与对照组客观有效率(objective response rate,ORR)分别为25.0%和18.3%,疾病控制率(disease control rate,DCR)分别为80.0%和73.3%,差异均无统计学意义(P=0.375,P=0.388);2)试验组与对照组1、2、3年生存率分别为(69.6%vs.62.5%)(39.7%vs.21.3%)(26.8%vs.13.3%),中位生存时间为22个月(95%CI:16.817~27.183)vs.16个月(95%CI:11.890~20.110),试验组较对照组生存率提高、生存时间延长,差异具有统计学意义(P=0.033).3)试验组与对照组中位疾病进展时间(time to progression,TTP)分别为9、8个月,差异无统计学意义(P>0.05).结论:重组人血管内皮抑制素窗口期联合化疗较常规应用方案联合化疗提高晚期大肠癌患者的1、2、3年生存率,延长中位生存时间.
    • 柳艳飞; 金红艳; 葛四平; 田勇; 王晓凤; 何为; 刘倩
    • 摘要: 目的 探讨恩度联合吉西他滨及铂类治疗非小细胞肺癌 (NSCLC) 的效果及对患者P糖蛋白 (P-gp) 表达的影响.方法 将NSCLC初治患者80例分为2组,其中使用铂类结合吉西他滨及恩度化疗患者38例为观察组,使用铂类结合吉西他滨化疗患者42例为对照组.观察2组患者近期治疗效果、生存状况、不良反应及P-gp定性状况.结果2组均无CR患者,观察组总有效率为34.21%,高于对照组的23.81%,但差异无统计学意义 (P> 0.05);观察组平均生存时间为 (17.25±3.46) 月,高于对照组的 (14.89±3.16) 月,但差异无统计学意义 (P> 0.05); 2组患者在心电图、血液血毒性、胃肠道反应及肝肾功能损伤等不良反应方面对比,差异无统计学意义 (P> 0.05).治疗后观察组P-gp阳性率为39.47%,低于对照组的59.52%,差异有统计学意义 (P <0.05).结论 恩度联合吉西他滨及铂类可一定程度提高晚期NSCLC患者病情缓解率及延长患者生存时间,同时可降低患者P-gp阳性表达率.%Objective To investigate the efficacy of Endo combined with gemcitabine and platinum in the treatment of non-small cell lung cancer (NSCLC) and its effect on the expression of P-glycoprotein (P-gp) in patients. Methods Eighty NSCLC patients were divided into two groups. Among them, 38 cases were treated with platinum combined with gemcitabine and Endi chemotherapy, and 42 cases were treated with platinum combined with gemcitabine chemotherapy as control group. Observe the short-term treatment effect, survival status, adverse reactions and qualitative status of P-gp in the two groups of patients. Results There were no patients with CR in both groups. The total effective rate was 34.21% in the observation group and 23.81%in the control group, but the difference was not statistically significant (P> 0.05). The average survival time in the observation group was (17.25 ± 3.46) months. In the control group (14.89 ± 3.16) months, the difference was not statistically significant (P> 0.05); the patients in the 2 groups were compared in adverse reactions such as electrocardiogram, hematologic toxicity, gastrointestinal reactions, and liver and kidney function impairments. Statistical significance (P> 0.05). The positive rate of P-gp conversion in the observation group was 39.47%, which was lower than the 59.52% in the control group. The difference was statistically significant (P < 0.05). Conclusion Enodi combined with gemcitabine and platinum can improve the remission rate and prolong survival time of patients with advanced NSCLC to a certain extent, and can reduce the positive rate of P-gp expression in patients.
    • 王燕; 马丽; 尤戈; 张丽敏; 南克俊
    • 摘要: 目的 观察吉西他滨联合奥沙利铂(GEMOX)方案联合恩度一线治疗晚期胆道系统肿瘤的近、远期疗效和毒副反应.方法 选取ⅣB期BTC患者45例,分为恩度联合组20例和单纯化疗组25例.单纯化疗组:吉西他滨1 000 mg/m2、奥沙利铂100 mg/m2;恩度联合组:GEMOX方案+恩度注射液15 mg静滴3~4h,21 d为1个周期.2个周期后KPS评分评价生活质量(QOL),NCI CTC 3.0标准评价毒副反应,并观察疾病无进展生存时间(PFS)和总生存时间(OS).结果 联合组CR 1例、PR 4例、SD 11例、PD 4例,RR 25%,DCR 80%,中位PFS 9个月,中位OS 14个月,QOL改善稳定率为85%;单纯化疗组CR 1例,PR 4例、SD 12例、PD 8例,RR 20%,DCR68%,中位PFS 7个月,中位OS 9个月,QOL改善稳定率为60%.2组中位PFS差异有统计学意义(P>0.05),2组中位OS差异无统计学意义(P>0.05).2组患者主要毒副反应包括骨髓抑制、胃肠道反应、肝脏毒性及外周神经炎等,2组比较差异无统计学意义(P>0.05).结论 GEMOX方案联合恩度一线治疗转移性BTCs疗效较好,且耐受性较好,值得临床应用和进一步观察.
    • 韦婕; 陈建; 胡冰; 季楚舒
    • 摘要: Objective To observe the effects of endostar at different doses by intraperitoneal injection in mice model bearing tumor ascites.Methods The tumor ascites model was established with EAC cells by intraperitoneal injection.A hundred and sixty mice were randomly assigned into 5 groups,32 rats in each group,which were respectively administered with the same volume of NS (control group),12.5 mg · kg-1 endostar,25 mg · kg-1 endostar,50 mg · kg-1 endostar,and 100 mg · kg-1 endostar every other day.The body mass,abdominal circumference and lifecycle of the mice in each group were recorded.The characteristics of ascites were observed and the permeability of peritoneal capillaries was measured.Results (1) Thirteen mice were randomly selected in each group for anatomy at Day 7 and the incidence of ascites was 80%.(2) There was significant difference in body mass between the control group and 100 mg · kg-1 group (P < 0.05),while no difference was found among all the other endostar groups (P > 0.05).(3) Compared with the control group,there were significant differences in abdominal circumference in 50 mg · kg-1 group and 100 mg · kg-1 group (P < 0.05).No differences were found in the other endostar groups (P > 0.05).(4) The degree of bloody effusion decreased with the increased dose of endostar.(5) There were no significant differences in the survival time and OD540 value between each endostar group and the control group (P > 0.05).Conclusions The endostar effect on bloody effusion is dose-related.Compared with other doses,50 mg · kg-1 and 100 mg · kg-1 endostar have significant effect on ascites,which can be regarded as the effective doses of cavity-treatment.%目的 观察不同剂量重组人血管内皮抑素(恩度)对腹水瘤小鼠腹水疗效的差异.方法 建立腹水瘤小鼠模型.将160只小鼠随机分成5组,每组32只,依次给予相同体积的生理盐水(Control组)、12.5 mg·kg-1恩度、25 mg·kg-恩度、50 mg·kg-恩度、100 mg·kg-1恩度,隔天给药.记录各组小鼠的体质量、腹围及生存期,观察腹水的性状,检测腹膜通透性.结果 (1)第7天各组随机解剖13只小鼠检测腹膜通透性,观察到小鼠腹水发生率为80%;(2)体质量方面,仅100 mg·kg-1剂量组与Control组的差异有统计学意义(P<0.05),余剂量组比较均差异无统计学意义(P>0.05);(3)腹围方面,对比Control组,50 mg·kg-1和100 mg·kg-1剂量组比较差异有统计学意义(P<0.05),余剂量组比较均差异无统计学意义(P>0.05);(4)随着恩度剂量增加,血性积液程度整体上呈减少趋势;(5)与Control组相比,各恩度剂量组的生存期、540 nm波长处Evan蓝的吸光度(OD540)值的比较均差异无统计学意义(P>0.05).结论 恩度对血性积液的效果与剂量相关.50、100 mg·kg-1剂量组相对其余剂量组腹水抑制作用明显,为恩度腔内治疗的有效剂量.
    • 李雪芹; 王存德; 龚泉; 李仕娟; 陈曦
    • 摘要: 目的 探讨鸦胆子油乳注射液配合恩度治疗恶性胸腔积液的疗效、安全性及患者生活质量改善情况.方法 研究观察2013年7月~2016年7月住院的恶性胸腔积液患者41例,随机分为联合治疗组22例和恩度单药治疗组19例,分析两组患者在疗效、药物不良反应、生活质量方面的差异.结果 联合治疗组总有效率较单药治疗组提高(P<0.05),不良反应轻,两组患者的生活质量均有所改善,且联合治疗组生活质量改善率较单药治疗组提高(P<0.05).结论 鸦胆子油乳注射液配合恩度治疗恶性胸腔积液疗效较恩度单药治疗略有提高,不良反应患者可耐受,能改善恶性胸腔积液患者的生活质量,具有一定的临床价值.
    • 丰俊东; 罗威; 秦叔逵; 吴穷; 王晓萍; 殷晓进; 孙新臣; 曲文书; 叶庆
    • 摘要: 目的 观察新型重组人血管内皮抑素(Endostar,恩度)联合放疗在不同时间、恩度给药剂量、放疗剂量条件下对小鼠肝癌移植瘤的抑瘤效果.方法 建立小鼠肝癌移植瘤模型.根据不同给药时间,分别将60只荷瘤小鼠按照给药剂量、是否联合放疗进行分组,每组10只;隔日测量肿瘤长径与短径;对比不同给药时间各分组的抑瘤效果.将小鼠随机分为6组,每组30只,处理方法同早给药方式分组,分析荷瘤小鼠的生存期.采用MTT法观察恩度浓度、射线剂量对协同作用的影响.采用Western blotting法检测不同给药方式各组中EGF、Flt-1蛋白的表达.采用免疫组化法检测荷瘤小鼠肿瘤微血管密度(MVD)、血管内皮生长因子(VEGF)、KDR的表达.采用电子显微镜观察细胞凋亡,流式细胞术检测细胞周期和凋亡率.结果 与对照组比较,单独应用恩度能够抑制小鼠移植瘤生长(P0.05).恩度联合放疗能够有效减少荷瘤小鼠MVD,8 mg/kg 恩度+RT组的MVD为8.6±1.3,显著低于其他各组(P0.05).Endostar in combination with radiation could significantly decrease MVD of hepatic carcinoma xenografts, the MVD in 8 mg/kg endostar+RT group was 8.6±1.3, lower than other groups (P<0.05).In 8 mg/kg endostar+RT group, the expression of VEGF and KDR was lower than other groups (P<0.05).Apoptoic changes were observed under lectron microscope in endostar in combination with radiation groups.Flow cytometry showed that cell cycles were blocked in S phase in 8 mg/kg endostar+RT group, and the cyto-apoptotic rate was higher than other groups (P<0.05).Conclusion The synergistic effect of endostar in combination with radiation is correlated to timing of administration, endostar dose and radiation dose, and the effect of early administration of endostar is superior to the late.
    • 郭茜; 齐秀恒; 武振明; 董久兴; 刘军
    • 摘要: Objective:To observe the clinical efficacy of rh -endostatin (endostar)combined with capecitabine regimen and capecitabine regimen alone in elderly patients with advanced colorectal cancer.Methods:Totally 86 ca-ses of advanced colorectal cancer elderly patients in our hospital from 2010 to 2013 were randomly divided into the treatment group and the control group,43 cases in each group.Control group was treated by capecitabine regimen a-lone,while treatment group was treated by endostar combined with capecitabine regimen.The short time curative effect,adverse reactions and survival rate of patients in two groups were compared.Results:The effective rate in treat-ment group (44.2%)was higher than that in control group (23.3%)(P0.05).There was also no statistical significance in the incidence of hypertension and serious event in cardiovascular system in two groups (P>0.05 ).1 -year survival rate and 2 -year survival rate in treatment group was higher than those in control group (P<0.05).Conclusion:Endostar combined with capecitabine regimen in the treatment of elderly advanced colorectal cancer will enhance the short time curative effect and survival rate,and with lower adverse reactions.It deserves to be further popularized clinically.%目的:观察卡培他滨单药联合重组人血管内皮抑素(恩度)方案一线化疗老年晚期结直肠癌的临床疗效。方法:选择2010年1月至2013年1月间收治的86例老年晚期结直肠癌患者,随机分为治疗组和对照组,每组43例。治疗组给予卡培他滨单药联合恩度方案,对照组给予卡培他滨单药方案。比较两组患者治疗后的近期疗效、不良反应及生存率。结果:治疗组患者的有效率(44.2%)明显高于对照组(23.3%),治疗组患者的临床获益率(83.7%)明显高于对照组(55.8%),差异有统计学意义(P<0.05)。治疗组患者的白细胞减少、血小板减少、手足反应、恶心呕吐及腹泻发生率与对照组比较,差异无统计学意义(P>0.05)。两组患者高血压、心血管等不良事件的发生率比较差异亦无统计学意义(P>0.05)。治疗组患者的1年生存率和2年生存率均明显高于对照组,差异有统计学意义(P<0.05)。结论:卡培他滨单药联合恩度方案可提高老年晚期结直肠癌的近期疗效和生存率,不良反应可耐受。
    • 李秋琳; 向旭东; 李高峰
    • 摘要: 目的:观察恩度、顺铂(PPD)腔内灌注治疗肺癌恶性血性胸水的有效性及安全性.方法:选取46例肺癌合并恶性血性胸腔积液患者,采用腔内灌注药物治疗,其中恩度组25例,顺铂组21例.具体方法:恩度每次60mg,每周2次,连用2周;顺铂每次60mg,每周2次,连用2周.治疗2周后评价并按世界卫生组织(WHO)胸腹水评价标准和不良事件通用术语标准(NCI-CTCAE)4.0版分别评价疗效、毒副反应及患者的生活质量.结果:46例患者均能进行客观疗效及安全性评价.腔内灌注恩度、PPD单药治疗的有效率分别为80.00%[完全缓解(CR)5例,部分缓解(PR)15例,无变化(NC)5例]和47.62%(CR2例,PR8例,NC11例).在生活质量方面,两组差异无统计学意义.3~4级毒副反应主要为白细胞减少、中性粒细胞减少、血小板减少、恶心呕吐和乏力,无治疗相关死亡发生.恩度组与顺铂组的消化道反应、骨髓抑制、肝功能损伤对比差异无统计学意义,两组胸痛比较差异有统计学意义.结论:采用恩度胸腔局部灌注可以较好地改善肺癌患者恶性血性胸腔积液的近期治疗效果,患者耐受性满意,并具有较好的临床安全性.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号